Searched for
GSK RESPIRATORY PORTFOLIO
GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapyBritain's GSK is set to acquire RAPT Therapeutics for $2.2 billion. This move brings the experimental food allergy drug ozureprubart into G...- GSK India plans big 'reinvention', MD Bhushan Akshikar revealsGlaxoSmithKline Pharmaceuticals is planning a major comeback in India. The company aims to double its revenue to ₹8,000 crore within the ne...
- GSK re-enters India’s cancer drug marketGlaxoSmithKline Pharmaceuticals is re-entering India's oncology market with the launch of Jemperli and Zejula, precision therapies for gyna...
- GSK boosts respiratory portfolio with $1.4 bn Aiolos Bio dealGSK will pay $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments. It will also make milestone ...
- Surge in viral infections pushes up pharma salesThe volumes were tepid in January, but with flu, Covid-19 and other viral infections spreading fast, February and March saw spikes in volum...
- Cipla scales up offerings, investments as it eyes global lung specialty leadershipDrugmaker Cipla said it is scaling up offerings and expanding access to medicines, inhaler devices, diagnostics, as it aspires to become th...
- Macquarie’s top 10 picks for India in a bear marketIndia’s benchmark indices are trading more than 30% off their record highs, as investors are concerned about the economic damage of the loc...
- Optimising product portfolio, focusing on key brands: GSK Pharmaceuticals"The business has embarked on it new strategy this year, as we put in place an optimal commercial structure and worked at building capabili...
- GSK Pharma in search of buyer for non-core brandsFor one of the oldest multinational drug makers in the country, the growth curve has been challenging.
- Select low-beta stocks may be better bets in this marketFive stocks to look at in the current market scenario marked by uncertainties.
- Lupin, Cipla, other top drugmakers in fray for Novartis’ brandsThe Novartis portfolio includes top-selling brand TOBI Podhaler, a drug prescribed for symptomatic relief to patients suffering from cystic...
- Demand muted because of economic factors: GSK Consumer MD Manoj Kumar"We've expanded foods where we can get the best returns, but as of now, it's in select markets. Foods business contributes close to 6% of o...
- GSK Pharma trying to find out what ammunition is needed to grow: MDThe Indian arm of British drugmaker GlaxoSmithKline (GSK) is planning a major initiative to wrestle back ground it had conceded.
- Brokerages raise Cipla's target price post inhaler launchAnalysts at Emkay Global Financial Services are of the view that the launch will have a strong positive impact on the company’s margins.
- Debt-free Lupin is ready for big acquisition: Vinita Gupta, CEO"We are a debt-free company with cash in balance and can raise over a billion dollar-and-half," said CEO Vinita Gupta .
- GSK India to benefit from global business swap deal with NovartisGlaxo will get Novartis’ vaccine portfolio, including anti-rabies products such as Rabipur, while transferring its smaller oncology busines...
- GlaxoSmithKline's CEO Andrew Witty backs India's pharma policy, cautious on acquisitions"I think it is wholly reasonable for a country that is having a tremendous growth with challenges has to think about pricing," Witty said.
- GlaxoSmithKline Pharma Q1 net up 37.52 per cent at Rs 169 croreGlaxoSmithKline Pharmaceuticals today reported a 37.52 per cent rise in its net profit to Rs 169.01 crore for the first quarter ended March...
- GlaxoSmithKline Pharmaceuticals Q3 net up 4.44% at Rs 152.34 croreGlaxoSmithKline today reported 4.44 per cent rise in net profit at Rs 152.34 crore for the quarter ended September 30, 2012 on back of robu...
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...
Load More
